Jpn. J. Infect. Dis., 53, 2000

Laboratory and Epidemiology ConnunicatiotLS
Seroprevalence of PaⅣovims B 1 9 among HIVトPositives in Japan

Hitomi Taguchil , Takeshi Yamadal , Takashi Takahashil , Mieko Gotohl ,Tetsuya Nakamura2and Aikichi Iwamoto l･2*

JDepartment ofInfectioZLS Diseases and 2Department ofInfectious Diseases andApplied Immunology, Institute of Medical Science, Unt'versio7 0f TTob70,
ShL'rokanedai 4‑6‑I, Minato‑ku, TTob/0 I 08‑8639
Communicated by Aikichi Iwamoto(Accepted March 22, 2000)

Human parvovimS B19 (B19) is a causative agent ofWe thank Dr. D. Chao for discussion. The work waserythemainfectiosum(fifth disease). It infects erythfoid

supported by grantsfromthe Organization for Phamaceuticalprogenitor cellsandthereby causes acute red cell aplasiain

Safetyand Research (OPSR) of Japan, Ministry of Healthand Welfare of Japan,andthe JapanScience Foundation.

patients under hematopoietic stress ( I).AsHIV‑ 1infectedpatientsare oRen placedunder hematopoietic stress by factors

such as zidovudine therapy, we examined seroprevalence
among HIV‑ I seropositives.
A total of 258 HIV‑ I seropositives treatedinour hospital

REFERENCE S

were examined for the presence ofanti‑B19 IgGand IgM

1. Young, N. (1998): Hematologicand hematopoietic con‑sequences ofB 1 9 parvoviruSinfection. Semin. Hemato1.,

antibodies by uslng reCOmbinant VPl and VP2 coatedmicroplates for ELISA (Denka Seiken Co. Ltd., Tokyo) (2).
Hemophiliacs, 1 13 cases were aquired HIV‑1 infection

2. Matsunaga, Y., Takeda, N., Yamazaki, S., Kamata, K.
and Kurosawa, D. (1995): Seroepidemiology of humanthrough contaminated blood products･ The remalnlng 145

parvovirus B 19 uslng reCOmbinant VPl+VP2 particle

25, 159‑172.

antigen. J. Jpn.Assoc. Infect. Dis., 69, 1371‑1375 (inwere probablyinfected via sexual routes.

The positive rate foranti‑B19 IgG was 96% (108/113) for
the former group and 50% (73/145) for the latter group

J叩aneSe).

3. Schwartz, T. F., Hottentrager, B.and Roggendorf, M.

(Table)･ The difference was significant (P < 0.001inx squaretest)･ The seroprevalence of B 1 9 IgGinthe non‑hemophiliac(1992): Prevalence of antibodies to parvovirus B19 inselected groups of patientsand healthyindividuals. ht.
J. Med. Microbiol. Virol. Parasitol. hfect. Dis., 276, 437‑

group, 50%, was almost the same asinthe healthy populationin Japan(2)I Theanti‑B19 IgG positivesamOng the latter442.

Our result showingthe higher seroprevalence ofanti‑B 1 9

4. Fukushima, Y., Okuyama, K., Komuro, K., Ueda, M.,
Fukutake, K.and Fujimaki, M. (1991): Elevated Clq‑

among hemophiliacs isinagreement with previous reports

bearlng lmmune COmplex in hemophiliacs with viralgroup were tested foranti‑B19 IgM, but all were negative.

infections. Jpn. J. Clin. Hemato1., 32, 1540‑1546 (in(3,4).

Japanese).

Table. Patients'profileand seroprevalence ofanti‑B 19 IgG
Patients

AgeCounts(n‑13‑53Male/Female

CD4

Hemophiliacs(year)
111I

13)(27.8)*/2(cells/LLl)

Non‑hemophiliacs

21‑68
1

1‑809(226)*(n=I(37.4)+

25/20

1‑74

1(252)I

Hemoglobin (g/dl)

7.9‑I 8.0 (13.5)+

6.2‑16.6 (13.2)+

Anti･B19 IgG positives (%)

108/I 13 (96) ++73/145 (50)++*Mean value HNumber of positives in total'Corresponding author: Fax: +8 I‑3‑5449‑5427, E‑mail:aikichi@
ims.u‑tokyo.ac.jp2145)